You've been automatically redirected here from, which is now part of Proteintech Group. Click here to dismiss this alert.
  • HEK293 expressed
  • Endotoxin-free
  • Animal-component free

Animal-free Recombinant Human IFN alpha 2B


Typically ≤ 0.12 ng/mL EC50

Species Reactivity




Cat no : HZ-1072



Technical Specifications

GeneID 3440
Species Human
Expression HEK293
Activity Typically ≤ 0.12 ng/mL EC50
Purity >95%
Molecular Mass 16 kDa, monomer, glycosylated
Formulation 1x PBS, See Certificate of Analysis for details
Species Reactivity human

Stability and Reconstitution

Stability and Storage Lyophilized proteins are stable for 1 year from the date of receipt if stored between (-20oC) and (-80oC). Upon reconstitution we recommend that the solution can be stored at (4oC) for short term or at (-20oC) to (-80oC) for long term. Repeated freeze thaw cycles should be avoided with reconstituted products.
Reconstitution Briefly centrifuge the vial before opening. It is recommended to reconstitute the protein in sterile 1xPBS containing 0.1% endotoxin-free recombinant human serum albumin (HSA).

Product Description

Animal-free Recombinant Human IFN alpha 2B is expressed in human 293 cells as a monomeric glycoprotein with an apparent molecular mass of 16 kDa. This cytokine is produced in a serum-free, chemically defined media. Production in human 293 cells offers authentic glycosylation which contributes to stability in cell growth media and other applications. The purity is greater than 95%.


Interferon alpha 2 is a type 1 interferon secreted by virus-infected cells to protect surrounding cells from the pathogen. Recombinant human interferon alpha 2 has been approved for therapeutic application in a range of human oncological and viral diseases. Three Interferon alpha 2 subvariants (2A, 2B, 2C) differ by only one or two amino acids at positions 23 and/or 34 of the mature protein (PMID: 25982860; 10672347; 1694761)





J Virol Methods

Screening of novel drugs for inhibiting hepatitis E virus replication.

Authors - Takashi Nishiyama

Antiviral Res

Antiviral candidates against the hepatitis E virus (HEV) and their combinations inhibit HEV growth in in vitro.

Authors - Takashi Nishiyama